REGENXBIO Follow-On Common Stock Offering
3/28/2017

Davis Polk advised the representatives of the underwriters in connection with the $75.9 million offering of 3,700,000 shares of common stock of REGENXBIO Inc. The common stock is listed on the NASDAQ Global Select Market under the symbol “RGNX.”

Based in Rockville, Maryland, REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s platform is currently being applied in the development of product candidates for a variety of diseases, including four internally developed product candidates and more than 20 product candidates being developed by REGENXBIO’s licensees.

The Davis Polk corporate team included partner Richard D. Truesdell Jr., counsel Jeffrey S. Ramsay and associate Zuo (Zoey) Yi. The intellectual property and technology team included counsel David R. Bauer and associates Bonnie Chen and Tilak Koilvaram. Counsel Marcie A. Goldstein provided FINRA advice. The tax team included partner Kathleen L. Ferrell and associates Elina Khodorkovsky and James Manzione. All members of the Davis Polk team are based in the New York office.